Geroprotectors

This category — pharmacological and nutraceutical agents proposed to target the hallmarks of aging directly — is where hope most outruns evidence. The honest assessment as of 2026: mechanistic promise is rich, human translation is thin, and industry funding distorts the published literature significantly.

The class as a whole

Two truths often missing from longevity content:

1. No supplement on the market has been shown to extend life in healthy adults at the magnitude of basic lifestyle interventions. No "longevity molecule" comes close to the effect of regular exercise, Mediterranean-pattern eating, or quitting smoking.

2. The gap between mechanistic promise and clinical translation is widening, not narrowing, for the entire emerging-longevity category. Five years of further research has, on net, deflated rather than confirmed most claims.

That said, this is an active and evolving field. Some agents (rapamycin, SGLT2 inhibitors) have stronger biological signals than others (resveratrol, NMN at typical over-the-counter (OTC) doses).

Tier 1: Best human evidence among geroprotectors

Rapamycin (and rapalogs) — Moderate (mechanistic / surrogate); Weak (hard outcomes)

The closest thing to a true gerotherapeutic in 2026.

The case for:

• Inhibiting mTOR (the mechanistic target of rapamycin, a central nutrient-sensing pathway) extends lifespan in mice 10–25%, replicated multiple times across sites and both sexes.
• Improves immune response to vaccination in older adults.^[1]
• The first randomized trial of intermittent low-dose rapamycin in healthy adults has now reported. PEARL — 48 weeks, placebo vs. 5 mg or 10 mg weekly — found the schedule well-tolerated, with adverse events no more common than on placebo and modest secondary signals (more lean mass and less pain in women on the higher dose).^[2] But it missed its primary endpoint — no change in visceral fat — and used compounded rapamycin later found to carry only about a third the bioavailability of generic sirolimus, so it establishes tolerability more than efficacy. Larger institution-run trials are underway.
• Mechanistic: directly inhibits mTOR, the most heavily targeted antagonistic hallmark.

The case for caution:

• Still no human RCT with hard longevity outcomes; PEARL's positive results were secondary endpoints, confined to subgroups.
• Side effects: mouth ulcers, lipid abnormalities, glucose dysregulation, immunosuppression.
• Dosing is far from optimized for healthy-adult use.
• Not approved for longevity indication; off-label use is increasing but unmonitored.

Practical: Some clinicians prescribe low-dose intermittent rapamycin (5–6 mg weekly) off-label. Without longer human safety data this remains experimental — appropriate only in informed adults working with a knowledgeable physician. Bear in mind what the drug actually is: rapamycin is a licensed immunosuppressant, and the weekly-pulse schedule used in longevity practice is an attempt to get the mTOR effect without the immunosuppression, not a demonstrated way of avoiding it. It is contraindicated in pregnancy and in active infection; live vaccines should be avoided on it; it impairs wound healing (stop before elective surgery); and it is metabolised by the CYP3A4 enzyme, so it interacts with the same enzyme flagged elsewhere on this page for quercetin, berberine, and grapefruit. Anyone taking it needs periodic lipids, fasting glucose or HbA1c (a marker of longer-term blood sugar), and a complete blood count (CBC) — the three things it most reliably disturbs.

Metformin — Moderate

A widely studied biguanide originally for type 2 diabetes (T2D).

The case for:

• AMPK activator (the catabolic counterweight to mTOR).
• Multiple cohorts (UKPDS extension, CPRD database) showed lower all-cause mortality in T2D patients on metformin vs. sulfonylureas. The much-repeated claim that metformin users outlive non-diabetic controls comes from one 2014 analysis and has been heavily criticised for immortal-time and comparator bias — sulfonylureas are themselves associated with harm, so "better than a sulfonylurea" is a low bar. Treat it as an association with a plausible confound, not evidence of a geroprotective effect.
• The TAME (Targeting Aging with Metformin) trial was designed to evaluate aging endpoints in non-diabetic adults, but it has never been funded or enrolled — it is a proposal, not a study in progress. Nothing is pending.

The case for caution:

• Some evidence that it blunts the adaptations to exercise — the mitochondrial and insulin-sensitivity gains from aerobic training in older adults (Konopka 2018), and, in a 2026 randomized trial, the vascular and blood-pressure adaptations to training in adults at metabolic risk.^[3] Concerning for active adults relying on training for longevity.
• Vitamin B12 deficiency risk with chronic use.
• Modest gastrointestinal (GI) side effects.
• No approved indication for healthy non-diabetic use.

Practical: For healthy adults, the cost-benefit currently favors not using metformin off-label. The exercise interaction is concerning. For prediabetics or T2D, it's the established first-line drug.

SGLT2 inhibitors (empagliflozin, dapagliflozin) — Strong (in disease populations)

A newer class — sodium-glucose cotransporter-2 (SGLT2) inhibitors block glucose reabsorption in the kidney — with surprising longevity-relevant signals.

The case for:

• Reduce all-cause mortality in type 2 diabetes, heart failure (HF), and chronic kidney disease (CKD) populations (EMPA-REG, DAPA-HF, EMPEROR trials).
• Pleiotropic effects beyond glucose: reduced cardiac remodeling, reduced renal decline, improved autophagy markers.
• Hypothesized as longevity drugs in healthy adults; early trials beginning.

The case for caution:

• Approved only for T2D, HF, and CKD.
• Side effects: increased urinary-tract and genital yeast infections, rare diabetic ketoacidosis.
• No safety/efficacy data in healthy adults.

Practical: For longevity-only off-label use in healthy adults, the evidence is currently insufficient to recommend.

GLP-1 receptor agonists (semaglutide, tirzepatide) — Moderate (and growing)

The newest, most contested entry in Tier 1. These glucagon-like peptide-1 (GLP-1) receptor agonists are the first drug class to move validated epigenetic aging clocks in a randomized human trial (GrimAgeV2 −2.26 years over 32 weeks) — though that signal comes from a small, exploratory, not-yet-peer-reviewed analysis in an atypical population, so read it as suggestive rather than settled. On firmer footing: a 20% reduction in major cardiovascular events (SELECT) and durable double-digit weight loss in non-diabetic adults. The same biology that drives those benefits also drives meaningful muscle and bone loss unless the patient eats enough protein and trains. Off-label "microdosing" for healthy adults is plausible but unproven and carries real compounding-pharmacy risks.

Practical: For an adult with overweight/obesity and cardiometabolic risk, the evidence is now strong enough to consider seriously. For a healthy normal-BMI adult chasing longevity alone, the case is interesting but not yet made — and never start without protein and resistance training in place.

→ Full treatment in GLP-1 receptor agonists: Ozempic, Wegovy, and the longevity question.

Tier 2: Mechanistically interesting, weak human evidence

NAD+ precursors: NMN and NR

Both reliably elevate blood NAD+ at 250–1000 mg/day. Whether this translates to clinical benefit in healthy adults is essentially unproven.

• Muscle insulin sensitivity gains in postmenopausal prediabetic women with NMN 250 mg.^[4]
• Small reduction in systolic blood pressure (SBP) with NR 1000 mg in stage-1 hypertensives.^[5]
• NR 2000 mg in obese men — completely negative for insulin sensitivity, mitochondrial function, body composition.^[6]

A new concern: NR may raise 2-PY and 4-PY (terminal breakdown products of NAD+ metabolism), recently linked to cardiovascular events in observational data.^[7] Biological significance unclear.

Regulatory note: NMN's status has been unstable. In late 2022 the US FDA concluded NMN is excluded from the dietary-supplement definition because it had earlier been authorized for investigation as a new drug (the filing behind the pharmaceutical candidate MIB-626), throwing its US over-the-counter availability into legal limbo; after an industry lawsuit the agency suspended enforcement in late 2024, and its status remains unsettled. NR (Niagen) has been on stable footing throughout.

Practical: The hype substantially outruns the evidence. Save the money. The broader vitamin B3 picture — niacin, nicotinamide, and whether NAD+ truly declines with age — is in B vitamins.

Urolithin A (Mitopure)

The best industry-funded randomised-trial data of any novel longevity compound. The ATLAS trial in 88 overweight middle-aged adults found roughly 12% leg-strength gain, 10% higher peak oxygen uptake (VO₂), and reduced inflammatory markers — but the primary endpoint (peak power) was missed.^[8]

• Only 30–40% of people convert dietary ellagitannins (pomegranate, walnuts) to urolithin A endogenously.
• All trials are sponsor-run (Amazentis); no hard outcomes studied.

Practical: A defensible niche option for older adults with sarcopenia who don't endogenously convert. For most, eating pomegranate and walnuts is the cheaper bet.

Spermidine

Rich animal data and a striking observational signal — the Bruneck cohort showed highest tertile dietary intake had 39% lower all-cause mortality.^[9]

But the SmartAge trial in 100 older adults was negative on its primary cognitive endpoint.^[10]

Practical: Dietary intake from Mediterranean-style eating (legumes, mushrooms, aged cheese, wheat germ, natto) is preferable to wheat germ extract pills.

Quercetin

500–1000 mg/day shows modest BP-lowering (~2–3 mmHg SBP). Phytosomal forms (Quercefit) better absorbed.

The senolytic dasatinib + quercetin protocol from the Mayo Clinic Kirkland group has reduced senescent-cell markers in human pilots, but dasatinib is a prescription leukemia drug — this is not a self-administration regimen.

Caution: Quercetin is a CYP3A4 inhibitor with real interactions (statins, cyclosporine, warfarin).

Tier 3: Hyped but weak human evidence

Resveratrol

The cautionary tale of the field. Extreme bioavailability problems (<1% oral), two decades of human trials, disappointingly inconsistent results.

• RESHAW (postmenopausal women, 150 mg/day) is the most positive trial — single-site, industry-funded.^[11]
• Yoshino 2012,^[12] Poulsen 2013,^[13] and others are largely null.

It also failed to extend lifespan in the NIA Interventions Testing Program (ITP) — the same multi-site mouse program where rapamycin and acarbose succeed.^[14] Red wine contains too little resveratrol to matter (~0.3–1 mg per glass). Whole-food polyphenol diversity beats isolated resveratrol as a defensible recommendation.

Taurine

Got Science cover treatment with a 12% mouse lifespan extension claim.^[15] But a 2025 Science paper directly contradicted the central premise, showing circulating taurine does not consistently decline with age in humans, monkeys, or mice.^[16]

Practical: Currently speculative. No RCT in healthy 35–55-year-olds targeting longevity.

GlyNAC (glycine + N-acetylcysteine)

Comes entirely from the Sekhar lab at Baylor — small pilot trials showing improvements in glutathione, mitochondrial function, and aging biomarkers in older adults at 100 mg/kg/day of each.

Independent replication is absent, and trial sizes are small.

NAC alone (600–1800 mg/day) has solid evidence for reducing flare-ups of chronic obstructive pulmonary disease (COPD) and is the standard antidote for acetaminophen overdose. Glycine alone (3 g pre-bed) has small Japanese trials suggesting modest sleep benefit.

Berberine

500 mg, 2–3× daily has strong short-term evidence for glucose and lipid lowering — comparable to metformin in head-to-head trials, with LDL-cholesterol reductions of ~15 mg/dL, apparently by boosting the liver's LDL-clearance pathway (the same pathway PCSK9-inhibitor drugs act on).

But berberine has no diabetes-prevention RCTs, no cardiovascular outcome trials, and no proven longevity equivalence to metformin despite being marketed as "natural metformin."

Caution: Potent inhibitor of the CYP3A4 drug-metabolising enzyme and of P-glycoprotein (a drug-transport pump), with real interactions affecting statins, cyclosporine, dabigatran, and many blood-pressure medications. Gastrointestinal side effects in 10–35% of users.

Low-dose lithium orotate

Only ecological/observational evidence — drinking-water lithium associates inversely with suicide and dementia rates across multiple meta-analyses.

A landmark 2025 Nature paper showed endogenous brain lithium is depleted in mild cognitive impairment and Alzheimer's disease, and that low-dose lithium orotate reversed pathology in mice.^[17] No RCT of microdose lithium orotate exists in healthy adults.

The supplement is safe at these doses but the longevity evidence is purely hypothesis-generating.

Astaxanthin

The one antioxidant carotenoid with an actual lifespan signal in the gold-standard mouse program. The NIA Interventions Testing Program — which runs each compound across three sites in genetically diverse mice — found astaxanthin extended median lifespan about 12% in males (p = 0.003).^[18] The catch is exactly the kind of detail the supplement market omits: the benefit was male-only — female lifespan was not significantly affected — a reminder that even a compound with a real signal can act in a sex-specific way rather than uniformly. Human data is limited to skin photoprotection (4–12 mg/day) and some metabolic markers; no human longevity outcomes.

Fisetin

A flavonoid marketed aggressively as an elite senolytic. The senescent-cell-clearing claims rest on preclinical data, and human trials are ongoing — but when the ITP tested fisetin head-on, it did not extend lifespan in either sex at the dose and schedules used.^[19] Worth tracking as senolytic research, not worth treating as an established longevity supplement. See Hallmarks of aging for the senescence picture.

Calcium alpha-ketoglutarate (Ca-AKG) — Weak (human); preliminary

A caloric-restriction-mimetic angle: αKG is a central metabolite of the cell's main energy-producing (tricarboxylic acid, TCA) cycle and a cofactor for the enzymes that maintain the epigenome, and tissue αKG falls with age. Late-life Ca-AKG feeding extended median lifespan and compressed morbidity in mice — significant in females (~16% median), numerically smaller and non-significant in males.^[20] The headline human data is an open-label study of the Rejuvant Ca-AKG formulation in 42 adults reporting an average ~8-year reduction in TruAge epigenetic age over ~7 months.^[21] That result is striking but uncontrolled, unblinded, and unreplicated — DNA-methylation clocks are noisy at the individual level and prone to regression-to-the-mean artifacts without a placebo arm.

Practical: Mechanistically reasonable, but the human evidence is hypothesis-generating only. Controlled trials are underway.

Sulforaphane (broccoli-sprout extract) — Weak

The prototypical dietary activator of Nrf2 — the master switch that turns on the cell's own antioxidant and detoxification enzymes. Human trials exist but stop at surrogate and disease-symptom endpoints, not aging outcomes — modest behavioral change in autism spectrum disorder,^[22] and small effects on fasting glucose in prediabetes that depend on baseline gut microbiota.^[23] No lifespan, healthspan, or aging-biomarker outcomes in humans, and bioavailability varies widely with the myrosinase content of the preparation.

Practical: Eating cruciferous vegetables (broccoli, broccoli sprouts) is a defensible whole-food bet; isolated extracts have no longevity evidence above that.

What to actually do

For a healthy 35–55-year-old, the realistic options are:

1. Skip the geroprotector category entirely — focus on sleep, exercise, diet, and the core supplements. Captures 95%+ of available benefit at much lower cost and risk.

2. For those willing to experiment — a minimal "biology-aware" approach:

   • Optional creatine (already in the core supplements)
   • Optional spermidine via diet (legumes, mushrooms, aged cheese)
   • Optional polyphenol-rich diet (berries, EVOO, dark chocolate, tea)
   • These are food, not supplements

3. For those drawn to pharmacological geroprotectors — work with a clinician knowledgeable in this area, not a marketing site. Rapamycin and SGLT2 inhibitors are the only agents currently with substantive biological signal, and both have meaningful side effects.

The "longevity stack" sold online — NMN, resveratrol, urolithin A, spermidine, lithium orotate, plus 10 other compounds — is currently unsupported by human RCT evidence and represents the worst kind of cocktail-of-everything approach.

Cautions and interactions

This is the one category on the site where the agents are pharmacologically active enough to hurt you, and several are prescription drugs being used off-label. The headline risks:

• CYP3A4 is the common thread. Rapamycin, quercetin, berberine, and grapefruit all act on or through the CYP3A4 enzyme, which also metabolises statins, many calcium-channel blockers, several anticoagulants, and most immunosuppressants. Stacking them is how people get unexpected drug levels. Any of these alongside prescription medication needs a pharmacist's review, not a forum post.
• Rapamycin — an immunosuppressant. Contraindicated in pregnancy and active infection; avoid live vaccines; impairs wound healing (stop before elective surgery). Monitor lipids, fasting glucose or HbA1c, and CBC.
• Metformin — B12 depletion with chronic use (check it annually), GI intolerance, and a blunting of the mitochondrial adaptations to exercise that is a genuine argument against it for an active adult. Contraindicated in significant renal impairment.
• Berberine — a potent CYP3A4 inhibitor and a genuine hypoglycaemic; combining it with metformin, a sulfonylurea, or insulin risks hypoglycaemia. Contraindicated in pregnancy.
• Dasatinib (in senolytic protocols) — a chemotherapy agent, with the bleeding, cytopenia, and pleural-effusion profile that implies. It has no place in unsupervised use.
• NAD⁺ precursors (NMN, NR) — the honest caution is not a known toxicity but an unknown one: no long-term human safety data, and a theoretical concern about feeding an existing occult malignancy that has not been resolved either way.
• High-dose niacin — distinct from NAD⁺ precursors and worth separating: its terminal metabolite 4PY promotes vascular inflammation.^[24]

Anyone on anticoagulants, immunosuppressants, antidiabetics, or with a cancer history should treat this entire category as prescription territory.

Further reading

• López-Otín C et al. Hallmarks of aging: An expanding universe. Cell 2023.^[25]
• Mannick JB et al. TORC1 inhibition enhances immune function in the elderly. Sci Transl Med 2018.^[26]
• Ferrell M et al. A terminal metabolite of niacin promotes vascular inflammation. Nat Med 2024.^[27]
• Singh A et al. Urolithin A: ATLAS trial. Cell Reports Medicine 2022.^[28]
• Schwarz C et al. SmartAge: Spermidine and Cognition. JAMA Network Open 2022.^[29]
• Yoshino M et al. NMN improves muscle insulin sensitivity in postmenopausal prediabetic women. Science 2021.^[30]
• Moel M et al. Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results. Aging 2025.^[31]
• Aron L et al. Lithium deficiency and the onset of Alzheimer's disease. Nature 2025.^[32]
• Asadi Shahmirzadi A et al. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice. Cell Metab 2020.^[33]
• Demidenko O et al. Rejuvant (Ca-AKG) and TruAge epigenetic age. Aging 2021.^[34]
• Rapamycin for longevity: pros, cons, and future perspectives. Front Aging 2025.^[35]
• Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nature Aging 2023.^[36]

---